Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegalovirus prophylaxis.

COI Statement

Ethics approval and consent to participate: This study was approved by the Institutional Review Board and Ethics Committee of the Institute of Hematology and Blood Diseases Hospital. The ethics committee approved the waiver of informed consent owing to the retrospective nature of the review. All human data of patients’ records were confirmed for collection in accordance with the relevant guidelines and regulations. Competing interests: The authors declare no competing interests.

References:

• Kołodziejczak M, Gil L, de la Camara R, Styczyński J. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Ann Hematol. 2021;100:763–77. https://doi.org/10.1007/s00277-021-04428-9
• Sugaya N, Kimura H, Hara S, Hoshino Y, Kojima S, Morishima T, et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8 + T cells in patients with chronic active EBV infection. J Infect Dis. 2004;190:985–8. https://doi.org/10.1086/423285
• Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001. https://doi.org/10.1182/blood-2008-09-178046
• Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794–802. https://doi.org/10.1093/cid/cit391
• Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99:346–52. https://doi.org/10.3324/haematol.2013.087338